LY 2189102

Drug Profile

LY 2189102

Alternative Names: IL-1β antibody - Eli Lilly; LY2189102

Latest Information Update: 29 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antibodies; Antihyperglycaemics; Antirheumatics
  • Mechanism of Action Immunosuppressants; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 17 Apr 2013 Discontinued - Phase-I for Cardiovascular disorders in USA (Parenteral)
  • 16 Sep 2011 Final efficacy and adverse events data from a phase II trial in Type-2 diabetes mellitus presented at the 47th Annual meeting of the European Association for the Study of Diabetes (EASD-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top